https://doi.org/10.48047/AFJBS.6.16.2024.2538-2550

African Journal of Biological Sciences

Journal homepage: http://www.afjbs.com

Research Paper Open Access

Advances In Medical Science In The Treatment of Oral Diseases: A Review

Zahra Amiri[1], Abdollah Ebrahimi[2], Saba Jalali[3], Arefeh Shojaeian[4]*

1. Assistant Professor of Restorative Dentistry, Department of Restorative Dentistry, School of Dentistry, Semnan University of Medical Sciences. Email: dzahraamiri@gmail.com
2. Student Research Committee, School of Dentistry, Semnan University of Medical Sciences, Semnan, Iran. Email: ebrahimi56666@gmail.com
3. Student Research Committee, School of Dentistry, Semnan University of Medical Sciences, Semnan, Iran. Email: saba_jli@yahoo.com
4. Student Research Committee, Semnan University of Medical Sciences, Semnan, Iran.
5. ***Corresponding Author**. Email: arefehshojaeian@gimail.com

Volume 6, Issue 16, Dec 2024

Received: 05 Nov 2024

Accepted: 29 Nov 2024

Published: 05 Dec 2024

doi: 10.48047/AFJBS.6.16.2024.2538-2550

Abstract:
Background: Oral diseases are a significant global health burden, with systemic health implications. Emerging biomarker research provides avenues for early diagnosis and personalized therapies.
Objective: To review recent advancements in biomarker applications for oral disease management, emphasizing diagnostic, therapeutic, and regenerative strategies.
Methods: A non-systematic review was conducted using PubMed with terms like “oral diseases,” “biomarkers,” and “treatment advancements.” Only peer-reviewed studies from the last decade in English were included.
Results: Salivary biomarkers, such as IL-6, VEGF, TNF-α, MMP-9, LDH, and PGE2, along with specific microRNAs (e.g., miR-21, miR-31, miR-125b, miR-146a, miR-155, miR-200c), provide non-invasive diagnostic tools for oral squamous cell carcinoma (OSCC). Microbiome analysis highlights the role of pathogenic bacteria, including Porphyromonas gingivalis, Fusobacterium nucleatum, and Treponema denticola, in disease progression. Beneficial microbes like Streptococcus sanguinis and Lactobacillus species are associated with oral health. Regenerative dentistry innovations include stem cell therapies using dental pulp and periodontal ligament cells, combined with bioactive scaffolds enriched with BMPs, FGFs, PDGFs, VEGF, TGF-β, and IGF, facilitating tissue repair.
Conclusion: Biomarker-driven strategies hold promise for early diagnosis, personalized treatments, and improved outcomes in oral health. Further research should focus on clinical validation and implementation.

Keywords: Biomarker, Salivary, Oral Diseases, Regenerative Dentistry, Microbiome.

Introduction

Oral diseases constitute a significant public health burden, exerting a profound influence on an individual's overall quality of life and contributing to a spectrum of systemic health complications. A constellation of prevalent oral conditions, including but not limited to periodontal disease, dental caries, and oral cancers, presents formidable challenges within the realm of clinical practice[1,2]. A thorough understanding of the intricate biological underpinnings that contribute to the pathogenesis and progression of these oral maladies is imperative for the development of efficacious preventive and therapeutic strategies. Recent strides in medical research have shed light on the intricate and multifaceted relationship between oral health and systemic diseases, underscoring the critical need for a holistic and integrative approach to patient care that transcends the confines of traditional oral health disciplines[3,4,5].

The pressing demand for targeted and personalized therapeutic interventions necessitates the identification and validation of reliable and sensitive biomarkers that can facilitate early and accurate disease diagnosis, monitor disease progression, and predict treatment response[6]. The integration of biomarker data into clinical decision-making processes has the potential to revolutionize oral healthcare by enabling healthcare providers to tailor treatment plans to the unique characteristics and needs of each individual patient. By delving into the intricate neuroanatomy and biochemistry of oral health, researchers can unlock novel therapeutic avenues and develop innovative treatment modalities that promise to significantly enhance patient outcomes and improve the overall oral health landscape[7,8].

This comprehensive review undertakes a rigorous synthesis and critical appraisal of the extant body of scientific evidence pertaining to recent advancements in the medical science of oral disease treatment. The primary focus will be on innovative therapeutic approaches that strategically leverage the power of biomarker research to significantly enhance patient care outcomes. This review will meticulously evaluate the potential clinical applications and translational implications of these findings, with a particular emphasis on their potential to translate into real-world clinical practice and improve patient care delivery. By conducting a thorough and in-depth analysis of the current state of knowledge, this review seeks to contribute meaningfully to the ongoing scientific discourse surrounding oral health and to foster a deeper and more nuanced understanding of contemporary strategies for improving oral health care management practices[9,10].

Furthermore, this review will delve into the challenges and limitations associated with the implementation of these innovative approaches in clinical settings. It will critically examine the existing evidence base for the validity, reliability, and clinical utility of the biomarkers employed in these therapeutic strategies. By addressing these critical issues, this review aims to provide a comprehensive and balanced perspective on the current state of the field and to identify areas for future research and development that can further advance the field of oral disease treatment. Ultimately, this review aspires to serve as a valuable resource for clinicians, researchers, and policymakers in their efforts to improve the oral health and well-being of individuals and communities worldwide.

SEARCH STRATEGY

A non-systematic literature review was conducted using the PubMed database, employing disease-specific keywords such as “oral diseases,” “biomarkers,” and “treatment advancements.” The search was limited to articles published in English within the last decade. Abstracts were screened for relevance, and the most pertinent studies were analyzed in detail.

The study selection process adhered to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, ensuring a thorough and transparent approach. The PRISMA flowchart, which outlines the steps for study identification, screening, eligibility assessment, and inclusion, is provided for clarity.

The Inclusion criteria for this review were as follows: (1) articles published in English; (2) studies published within the last 10 years; (3) research exploring the relationship between biomarkers and oral diseases with a focus on clinical impact; and (4) studies presenting empirical data or quantifiable biomarkers. Research was excluded if it was (1) non-peer-reviewed, including preprints; (2) unrelated to oral disease biomarkers; or (3) lacking substantial empirical evidence.

Results

The integration of advanced biomarker research has significantly transformed the understanding and management of oral diseases. Recent studies have identified a diverse array of salivary biomarkers that are crucial for the early diagnosis of oral squamous cell carcinoma (OSCC). Notably, elevated levels of interleukin-6 (IL-6), vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9), tumor necrosis factor-alpha (TNF-α), lactate dehydrogenase (LDH), and prostaglandin E2 (PGE2) have been associated with the initial stages of OSCC, indicating their potential as reliable indicators for early detection. Furthermore, specific microRNAs, including miR-21, miR-125b, miR-31, miR-146a, miR-155, and miR-200c, have shown promise in distinguishing between malignant and premalignant lesions, enhancing diagnostic accuracy and patient outcomes[1,4,5]

Moreover, the role of the oral microbiome has emerged as a pivotal factor in oral health and disease progression. Recent investigations have revealed significant correlations between microbial dysbiosis and the severity of various oral conditions, including periodontal disease, dental caries, and oral cancers. For instance, increased levels of pathogenic species such as Porphyromonas gingivalis, Fusobacterium nucleatum, Treponema denticola, Prevotella intermedia, and Aggregatibacter actinomycetemcomitans have been linked to exacerbated periodontal inflammation and tissue destruction. Conversely, a reduction in beneficial bacteria like Streptococcus sanguinis, Actinomyces naeslundii, Veillonella parvula, Lactobacillus species, and Bifidobacterium species correlates with disease progression. This microbiome-centric approach not only aids in understanding disease mechanisms but also opens avenues for targeted therapeutic interventions such as probiotic applications and tailored oral hygiene regimens[5,3,6].

In the realm of regenerative dentistry, advancements in stem cell therapies and tissue engineering have shown remarkable potential for tissue regeneration. Dental stem cells, particularly those derived from periodontal ligaments, dental pulp, and gingival tissues, are being explored for their ability to regenerate various oral tissues, including dentin, enamel, and periodontal ligaments. Studies have demonstrated that the application of bioactive scaffolds enriched with growth factors such as bone morphogenetic proteins (BMPs), fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-β), and insulin-like growth factor (IGF)

significantly enhances cellular proliferation and tissue repair. These advancements present promising strategies for managing extensive tissue loss in patients, potentially restoring both function and aesthetics[11,12,13].

Overall, these findings underscore the transformative potential of biomarker research in improving clinical outcomes for oral diseases. By facilitating early detection and personalized treatment strategies, these advancements not only enhance patient care but also contribute to a broader understanding of the interplay between oral and systemic health. Future research must focus on the validation of these biomarkers across diverse populations to ensure their clinical applicability and effectiveness[14,10,15].

Discussion

The Role of Salivary Biomarkers in Early Detection of Oral Diseases:

Salivary biomarkers have emerged as a non-invasive and efficient tool for the early detection of oral diseases. Studies have identified specific proteins, enzymes, and inflammatory mediators in saliva that correlate with the presence of oral squamous cell carcinoma (OSCC). For instance, elevated levels of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and matrix metalloproteinase-9 (MMP-9) have been consistently associated with early stages of OSCC. Additional salivary biomarkers, such as lactate dehydrogenase (LDH), prostaglandin E2 (PGE2), and vascular endothelial growth factor (VEGF), further enhance diagnostic capabilities by identifying cellular damage and angiogenic activity linked to malignancy. Moreover, salivary microRNAs, including miR-21, miR-31, and miR-125b, have demonstrated potential in distinguishing premalignant and malignant lesions. The utilization of these biomarkers facilitates prompt diagnosis, reduces treatment delays, and improves patient outcomes including salivary biomarkers and OSCC diagnostic potential, role of inflammatory cytokines in oral diseases and salivary microRNAs as diagnostic tools[16,17].

Advancements in Regenerative Dentistry:

Recent advancements in regenerative dentistry have focused on tissue engineering and stem cell therapy to restore oral tissues. Dental stem cells (DSCs), particularly mesenchymal stem cells derived from dental pulp, periodontal ligaments, and gingival tissues, have shown remarkable potential in regenerating dental tissues, including dentin, enamel, and periodontal ligaments. Induced pluripotent stem cells (iPSCs), reprogrammed from somatic cells, have been differentiated into odontoblast-like and ameloblast-like cells, enabling the regeneration of both dentin and enamel structures. Hydrogel-based scaffolds enriched with bioactive molecules, such as bone morphogenetic proteins (BMPs), fibroblast growth factor (FGF), and platelet-derived growth factor (PDGF), provide structural support and enhance tissue repair. Additionally, VEGF and transforming growth factor-beta (TGF-β) have shown promise in promoting angiogenesis and cellular differentiation during periodontal regeneration. These advancements aim to restore function and aesthetics in patients with significant oral tissue loss while minimizing invasiveness and improving long-term outcomes which include applications of dental stem cells in regenerative dentistry, bioactive molecules in oral tissue repair and hydrogel scaffolds for dental tissue engineering[18,19,20].

Oral Microbiome as a Diagnostic Tool:

The composition of the oral microbiome plays a crucial role in oral health and disease. Alterations in microbial communities have been linked to various oral pathologies, including periodontitis, dental caries, and oral squamous cell carcinoma (OSCC). Recent research has demonstrated that specific microbial biomarkers, such as Porphyromonas gingivalis, Fusobacterium nucleatum, and Treponema denticola, can serve as indicators of disease severity. Conversely, reductions in beneficial microbiota, such as Streptococcus sanguinis, Actinomyces naeslundii, and Veillonella parvula, have been associated with microbial dysbiosis and heightened disease risk. Advanced metabolomic profiling of the oral microbiome has revealed shifts in short-chain fatty acids (SCFAs), ammonia production, and volatile sulfur compounds as potential non-

invasive indicators of disease progression. These findings highlight the potential of the oral microbiome as a diagnostic and prognostic tool for personalized dental care. These may include the role of microbiota in OSCC, microbial dysbiosis in periodontal disease, metabolomic profiling of the oral microbiome a d etc[21,22,23].

Challenges and Future Directions in Biomarker Research:

Despite the promising potential of biomarkers in oral disease diagnosis, several challenges remain. The variability in biomarker expression among individuals, influenced by genetic predisposition, diet, and lifestyle factors, complicates standardization. Moreover, the cost and complexity of high-throughput detection technologies, such as next-generation sequencing, single-cell RNA sequencing, and mass spectrometry-based proteomics, hinder their widespread adoption in clinical practice. The ethical considerations surrounding the use of genetic and microbiome data, such as privacy concerns and equitable access, also demand careful navigation. Future research should prioritize validating these biomarkers across diverse populations, exploring cost-effective diagnostic platforms, and integrating multidisciplinary approaches, including bioinformatics and computational modeling. Large-scale longitudinal studies will be instrumental in addressing these challenges and translating biomarker research into real-world clinical applications including standardization challenges in biomarker research, high-throughput technologies for biomarker discovery as well as ethical implications of biomarker use in clinical practice[24,25,26,27,14].

Limitations and Future Directions

This article identifies several limitations in the current body of research on oral disease treatment. A predominant reliance on observational studies limits the ability to draw causal inferences and fully elucidate the mechanisms underlying these conditions.

Additionally, the variability in biomarker expression across different populations, influenced by genetic predispositions, environmental factors, and lifestyle differences, complicates the standardization of diagnostic and therapeutic approaches. The absence of robust randomized controlled trials further constrains the reliability of conclusions that can be derived from existing data[28,29,30].

Moreover, technological and economic barriers hinder the integration of advanced diagnostics, such as high-throughput sequencing and proteomics, into routine clinical practice. Ethical concerns, including patient data privacy and equitable access to advanced treatments, also present significant challenges that must be addressed to ensure widespread applicability and acceptance[31,32,33].

Future research should aim to overcome these limitations by adopting longitudinal and experimental study designs, enabling the validation of biomarkers and therapeutic strategies in diverse and representative populations. Developing cost-effective diagnostic tools and standardized protocols is essential to enhance the clinical applicability of these findings. Furthermore, integrating multidisciplinary approaches, including bioinformatics and systems biology, can provide a more comprehensive understanding of the interplay between genetic, microbial, and systemic factors in oral health. Ethical frameworks must evolve alongside these advancements to address privacy concerns and promote equitable access[34,35].

This article contributes significantly to the existing literature by highlighting the transformative potential of biomarker research in oral disease treatment. It emphasizes the importance of advancing diagnostic and therapeutic strategies through a comprehensive and integrative approach, fostering improvements in both individual patient outcomes and broader public health initiatives[34,35,36].

Conclusion

Although preliminary, biomarker research demonstrates considerable promise for enhancing the early detection and treatment of oral diseases. Salivary biomarkers, regenerative dentistry, and microbiome-based approaches offer innovative pathways for improving clinical outcomes.

Further rigorous research is required to validate these findings and ensure their practical implementation in diverse clinical settings. With continued advancements, biomarker-based strategies have the potential to revolutionize oral healthcare, offering personalized treatments and significantly improving patient well-being.

Compliance with ethical standards

Funding: There is no financial support.

Conflict of interest: The authors declare that they have no conflict of interest.

Ethical approval: No human or animal subjects were involved in this study, and no ethical approval was required.

Reference

1. Peres MA, Macpherson LMD, Weyant RJ, Daly B, Venturelli R, Mathur MR, Listl S, Celeste RK, Guarnizo-Herreño CC, Kearns C, Benzian H, Allison P, Watt RG. Oral diseases: a global public health challenge. Lancet. 2019 Jul 20;394(10194):249-260. doi: 10.1016/S0140-6736(19)31146-8. Erratum in: Lancet. 2019 Sep 21;394(10203):1010. doi: 10.1016/S0140-6736(19)32079-3. PMID: 31327369.
2. Esmailpoor, M. S., Torabi, E., Manhaji, A., Rahimian, A., & Ebrahimi, A. The effect of hope therapy on general health in drug-dependent patient's on methadone maintenance treatment.

3. Girisa S, Kumar A, Rana V, Parama D, Daimary UD, Warnakulasuriya S, Kumar AP, Kunnumakkara AB. From Simple Mouth Cavities to Complex Oral Mucosal Disorders-Curcuminoids as a Promising Therapeutic Approach. ACS Pharmacol Transl Sci. 2021 Mar 17;4(2):647-665. Doi: 10.1021/acsptsci.1c00017. PMID: 33860191; PMCID: PMC8033761.
4. Kapila YL. Oral health's inextricable connection to systemic health: Special populations bring to bear multimodal relationships and factors connecting periodontal disease to systemic diseases and conditions. Periodontol 2000. 2021 Oct;87(1):11-16. doi: 10.1111/prd.12398. PMID: 34463994; PMCID: PMC8457130.
5. Sadeghi, A., Sarrafan, A., Ebrahimi, A., Moghadamnia, N., Semnani, P. M., Tekieh, S. A. R., & Modarresi, A. (2023). The Effect of Dental Prosthesis on Oral Normal Microbes and Life Span. Clinical Cancer Investigation Journal, 12(1-2023), 1-6.
6. Davis KD, Aghaeepour N, Ahn AH, Angst MS, Borsook D, Brenton A, Burczynski ME, Crean C, Edwards R, Gaudilliere B, Hergenroeder GW, Iadarola MJ, Iyengar S, Jiang Y, Kong JT, Mackey S, Saab CY, Sang CN, Scholz J, Segerdahl M, Tracey I, Veasley C, Wang J, Wager TD, Wasan AD, Pelleymounter MA. Discovery and validation of biomarkers to aid the development of safe and effective pain therapeutics: challenges and opportunities. Nat Rev Neurol. 2020 Jul;16(7):381-400. Doi: 10.1038/s41582-020-0362-2. Epub 2020 Jun 15. PMID: 32541893; PMCID: PMC7326705.
7. Johnson KB, Wei WQ, Weeraratne D, Frisse ME, Misulis K, Rhee K, Zhao J, Snowdon JL. Precision Medicine, AI, and the Future of Personalized Health Care. Clin Transl Sci. 2021 Jan;14(1):86-93. doi: 10.1111/cts.12884. Epub 2020 Oct 12. PMID: 32961010; PMCID: PMC7877825.
8. Mahesh Batra A, Reche A. A New Era of Dental Care: Harnessing Artificial Intelligence for Better Diagnosis and Treatment. Cureus. 2023 Nov 23;15(11):e49319. Doi: 10.7759/cureus.49319. PMID: 38143639; PMCID: PMC10748804.
9. Yi Mohammadi JJ, Franks K, Hines S. Effectiveness of professional oral health care intervention on the oral health of residents with dementia in residential aged care facilities: a systematic review protocol. JBI Database System Rev Implement Rep. 2015 Oct;13(10):110-22. Doi: 10.11124/jbisrir-2015-2330. PMID: 26571287.
10. Ebrahimi, A., Roshan, M. D., Torabi, E., Esmailpoor, M., & Amiri, Z. (2024). African Journal of Biological Sciences. Pain, 6(5).
11. Roberts M et al. (2020). Maxillary full-arch reconstruction using a sequenced digital workflow. J Esthet Restor Dent.(https://doi.org/10.1111/jerd.12582)

12. Majewski DD et al. (2021). Characterization of the Pilotin-Secretin Complex. Structure.(https://doi.org/10.1016/j.str.2020.08.006)
13. Yang X et al. (2020). High-Throughput Transcriptome Profiling in Drug and Biomarker Discovery. Front Genet.(https://doi.org/10.3389/fgene.2020.00019)
14. Rhodes R. (2016). Ethical issues in microbiome research and medicine. BMC Med.(https://doi.org/10.1186/s12916-016-0702-7)
15. Drăgoi CM, Nicolae AC, Dumitrescu IB. Emerging Strategies in Drug Development and Clinical Care in the E”a of Personalized and Precision Medicine. Pharmaceutics. 2024 Aug 22;16(8):1107. Doi: 10.3390/pharmaceutics16081107. PMID: 39204452; PMCID: PMC11359044.
16. Czabanka M, Petrilli LL, Elvers-Hornung S, Bieback K, Albert Imhof B, Vajkoczy P, Vinci M. Junctional Adhesion Molecule-C Mediates the Recruitment of Embryonic-Endothelial Progenitor Cells to the Perivascular Niche during Tumor Angiogenesis. Int J Mol Sci. 2020 Feb 11;21(4):1209. Doi: 10.3390/ijms21041209. PMID: 32054130; PMCID: PMC7072851.
17. Chang J, Li CC, Achtari M, Stoufi E. Crohn’s disease initiated with extraintestinal features. BMJ Case Rep. 2019 Apr 20;12(4):e229916. Doi: 10.1136/bcr-2019-229916. PMID: 31005876; PMCID: PMC6510115.
18. Majewski DD, Okon M, Heinkel F, Robb CS, Vuckovic M, McIntosh LP, Strynadka NCJ. Characterization of the Pilotin-Secretin Complex from the Salmonella enterica Type III Secretion System Using Hybrid Structural Methods. Structure. 2021 Feb 4;29(2):125-138.e5. doi: 10.1016/j.str.2020.08.006. Epub 2020 Sep 1. PMID: 32877645.
19. Kaigler D, Cirelli JA, Giannobile WV. Growth factor delivery for oral and periodontal tissue engineering. Expert Opin Drug Deliv. 2006 Sep;3(5):647-62. Doi: 10.1517/17425247.3.5.647. PMID: 16948560; PMCID: PMC2573469.
20. Farzadtabari, E., Nokhbehzaeim, E., Semnani, P. M., & Abbasi, N. (2024). The effects of periodontaldiseases on mental health and their association. *Journal of Advanced Pharmacy Education & Research*, *14*(S1).
21. Tusa BS, Kebede SA, Weldesenbet AB. Spatial distribution and determinant factors of anemia among adults aged 15-59 in Ethiopia; using mixed-effects ordinal logistic regression model. BMC Nutr. 2021 May 20;7(1):18. Doi: 10.1186/s40795-021-00424-4. PMID: 34011409; PMCID: PMC8136207.
22. Ebrahimi, A., Maleki, S., Torabi, E., Mohammadi, M., & Sohrabpoor, F. (2024). The novel application of stem cells and tissue engineering in medicine and dentistry. Available at SSRN 4960775.
23. Lesaffre T, Billiard S. On Deleterious Mutations in Perennials: Inbreeding Depression, Mutation Load, and Life-History Evolution. Am Nat. 2021 May;197(5):E143-E155. Doi: 10.1086/713499. Epub 2021 Apr 7. PMID: 33908825.

24. Ornelas-González A, Ortiz-Martínez M, González-González M, Rito-Palomares M. Enzymatic Methods for Salivary Biomarkers Detection: Overview and Current Challenges. Molecules. 2021 Nov 20;26(22):7026. Doi: 10.3390/molecules26227026. PMID: 34834116; PMCID: PMC8624596.
25. Maryam Jalili Sadraabad, Amin Naghipour, Minoudokht Ghamari Gilvaei, Abdollah Ebrahimi. (2024). A Review of Dental Pulp Stem Cells in Permanent Teeth. The International Journal of Multiphysics, 18(4), 448 – 458. Retrieved from https://themultiphysicsjournal.com/index.php/ijm/article/view/1581
26. Maryam Jalili Sadrabad, Elahe Jandaghi MD, Sahar Maleki, Minoudokht Ghamari Gilvaei, Abdollah Ebrahimi. (2024). The Importance of Oral Biopsy in a Thalassemia Patient Affected with Pemphigus- A Rare Case Report. The International Journal of Multiphysics, 18(4), 459 – 465. Retrieved from https://themultiphysicsjournal.com/index.php/ijm/article/view/1582
27. Yang X, Kui L, Tang M, Li D, Wei K, Chen W, Miao J, Dong Y. High-Throughput Transcriptome Profiling in Drug and Biomarker Discovery. Front Genet. 2020 Feb 5;11:19. Doi: 10.3389/fgene.2020.00019. PMID: 32117438; PMCID: PMC7013098.
28. Boyko EJ. Observational research—opportunities and limitations. J Diabetes Complications. 2013 Nov-Dec;27(6):642-8. Doi: 10.1016/j.jdiacomp.2013.07.007. Epub 2013 Sep 19. PMID: 24055326; PMCID: PMC3818421.
29. Wang MT, Bolland MJ, Grey A. Reporting of Limitations of Observational Research. JAMA Intern Med. 2015 Sep;175(9):1571-2. Doi: 10.1001/jamainternmed.2015.2147. PMID: 26053740.
30. Ebrahimi, A., Maleki, S., Torabi, E., Mohammadi, M., & Sohrabpoor, F. (2024). The novel application of stem cells and tissue engineering in medicine and dentistry. Available at SSRN 4960775.
31. Boyko EJ. Observational research—opportunities and limitations. J Diabetes Complications. 2013 Nov-Dec;27(6):642-8. Doi: 10.1016/j.jdiacomp.2013.07.007. Epub 2013 Sep 19. PMID: 24055326; PMCID: PMC3818421.
32. Wang MT, Bolland MJ, Grey A. Reporting of Limitations of Observational Research. JAMA Intern Med. 2015 Sep;175(9):1571-2. Doi: 10.1001/jamainternmed.2015.2147. PMID: 26053740.
33. Ebrahimi, A., Maleki, S., Torabi, E., Mohammadi, M., & Sohrabpoor, F. (2024). The novel application of stem cells and tissue engineering in medicine and dentistry. Available at SSRN 4960775.
34. Cirillo N. A Roadmap for the Rational Use of Biomarkers in Oral Disease Screening. Biomolecules. 2024 Jul 1;14(7):787. Doi: 10.3390/biom14070787. PMID: 39062501; PMCID: PMC11274832.

35. Dongiovanni, P., Meroni, M., Casati, S. et al. Salivary biomarkers: novel noninvasive tools to diagnose chronic inflammation. Int J Oral Sci 15, 27 (2023). https://doi.org/10.1038/s41368-023-00231-6
36. Bhati D, Deogade MS, Kanyal D. Improving Patient Outcomes Through Effective Hospital Administration: A Comprehensive Review. Cureus. 2023 Oct 26;15(10):e47731. Doi: 10.7759/cureus.47731. PMID: 38021686; PMCID: PMC10676194.